肿瘤基础与临床
腫瘤基礎與臨床
종류기출여림상
JOURNAL OF BASIC AND CLINICAL ONCOLOGY
2014年
2期
137-139
,共3页
肿瘤%贫血%重组人促红细胞生成素%铁剂
腫瘤%貧血%重組人促紅細胞生成素%鐵劑
종류%빈혈%중조인촉홍세포생성소%철제
cancer%anemia%recombinant human erythropoietin%iron
目的：探讨不同补铁方法联合重组人促红细胞生成素（rhEPO）治疗肿瘤相关性贫血的有效性。方法78例肿瘤相关性贫血患者随机分为3组：A 组（n ＝26）予以 rhEPO 和琥珀酸亚铁，b 组（n ＝26）予以rhEPO 和每周1次的蔗糖铁，C 组（n ＝26）予以 rhEPO 和每周2次的蔗糖铁。比较治疗后3组患者的临床有效率、血红蛋白水平及 KPS 评分。结果治疗8周后 b 组总有效率达57.7%，C 组总有效率达88.5%，高于A 组的26.9%（P 均<0.05），其中 C 组又高于 b 组（P <0.05）；治疗8周后 b 组和 C 组血红蛋白水平、KPS评分改善情况均好于 A 组（P 均<0.05），C 组又明显好于 b 组（P <0.05）。结论补充铁剂联合 rhEPO 治疗肿瘤相关性贫血有较好的临床效果，其中静脉补充铁剂疗效优于口服，每周2次的静脉补充铁剂优于每周1次。
目的：探討不同補鐵方法聯閤重組人促紅細胞生成素（rhEPO）治療腫瘤相關性貧血的有效性。方法78例腫瘤相關性貧血患者隨機分為3組：A 組（n ＝26）予以 rhEPO 和琥珀痠亞鐵，b 組（n ＝26）予以rhEPO 和每週1次的蔗糖鐵，C 組（n ＝26）予以 rhEPO 和每週2次的蔗糖鐵。比較治療後3組患者的臨床有效率、血紅蛋白水平及 KPS 評分。結果治療8週後 b 組總有效率達57.7%，C 組總有效率達88.5%，高于A 組的26.9%（P 均<0.05），其中 C 組又高于 b 組（P <0.05）；治療8週後 b 組和 C 組血紅蛋白水平、KPS評分改善情況均好于 A 組（P 均<0.05），C 組又明顯好于 b 組（P <0.05）。結論補充鐵劑聯閤 rhEPO 治療腫瘤相關性貧血有較好的臨床效果，其中靜脈補充鐵劑療效優于口服，每週2次的靜脈補充鐵劑優于每週1次。
목적：탐토불동보철방법연합중조인촉홍세포생성소（rhEPO）치료종류상관성빈혈적유효성。방법78례종류상관성빈혈환자수궤분위3조：A 조（n ＝26）여이 rhEPO 화호박산아철，b 조（n ＝26）여이rhEPO 화매주1차적자당철，C 조（n ＝26）여이 rhEPO 화매주2차적자당철。비교치료후3조환자적림상유효솔、혈홍단백수평급 KPS 평분。결과치료8주후 b 조총유효솔체57.7%，C 조총유효솔체88.5%，고우A 조적26.9%（P 균<0.05），기중 C 조우고우 b 조（P <0.05）；치료8주후 b 조화 C 조혈홍단백수평、KPS평분개선정황균호우 A 조（P 균<0.05），C 조우명현호우 b 조（P <0.05）。결론보충철제연합 rhEPO 치료종류상관성빈혈유교호적림상효과，기중정맥보충철제료효우우구복，매주2차적정맥보충철제우우매주1차。
Objective To evaluate the efficacy of different iron supplements combined with recombinant human erythropoietin(rhEPO)in treatment of cancer related anemia. Methods Seventy-eight patients with cancer related anemia were randomized into three groups. The A group(n = 26)was treated with recombinant human erythropoie-tin and ferrous succinate;the b group(n = 26)was treated with recombinant human erythropoietin and intravenous iron sucrose supplementation(once a week);The C group(n = 26)was treated with recombinant human erythro-poietin and intravenous iron sucrose(twice a week). The clinical efficiency,hemoglobin levels and KPS scores of the three groups after treatment were compared. Results After 8 weeks of treatment,the response rate of the A group,the b group and the C group were 26. 9% ,57. 7% and 88. 5% respectively,the response rate of the b group and the C group were significantly higher than that of the A group(P < 0. 05),and that of the C group was better than that of the b group(P < 0. 05). After 8 weeks of treatment,the hemoglobin levels and KPS scores of the b group and the C group were better than those of the A group(P < 0. 05),and those of the C group was better than those of the b group(P < 0. 05). Conclusion RhEPO combined with iron supplements has better effect in the treatment of cancer related anemia,and intravenous iron was better than oral iron,intravenous iron supplementation of twice a week was better than once a week.
